EGFR and non-small cell lung carcinoma: Importantly, phosphorylated AKT (pAKT) was detected by IHC not only in 60% of examined samples from NSCLC patients after progression on EGFR-TKIs by different resistance mechanisms, but also in 11% of baseline samples, suggesting the pre-existence of pAKT-positive, intrinsically resistant clones.